{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:00:21Z","timestamp":1787796021572,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["No.UG1 CA233373"],"award-info":[{"award-number":["No.UG1 CA233373"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.esmoop.2024.102388","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T17:23:08Z","timestamp":1709572988000},"page":"102388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a\u00a0comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network\u2014Breast dataset (SCAN-B)"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-6585","authenticated-orcid":false,"given":"G.","family":"Villacampa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Par\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4649","authenticated-orcid":false,"given":"L.A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2311-4356","authenticated-orcid":false,"given":"A.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mar\u00edn-Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-3641","authenticated-orcid":false,"given":"P.","family":"Villagrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-2247","authenticated-orcid":false,"given":"C.M.","family":"Perou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"A.","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"S.M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.102388_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","article-title":"Dissecting the biological heterogeneity of HER2-positive breast cancer","volume":"59","author":"Schettini","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2024.102388_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/OP.21.00172","article-title":"Current and future management of HER2-positive metastatic breast cancer","volume":"17","author":"Mart\u00ednez-S\u00e1ez","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2024.102388_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-018-0098-y","article-title":"PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?","volume":"5","author":"Pond\u00e9","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2024.102388_bib5","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/S0140-6736(19)30653-1","article-title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial","volume":"393","author":"Pivot","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.102388_bib6","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","article-title":"Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2\u2013positive breast cancer: the SOLD randomized clinical trial","volume":"4","author":"Joensuu","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib7","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","article-title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102388_bib9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102388_bib11","doi-asserted-by":"crossref","first-page":"dju152","DOI":"10.1093\/jnci\/dju152","article-title":"Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer","volume":"106","author":"Prat","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.102388_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101965","article-title":"HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis","volume":"84","author":"Schettini","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2024.102388_bib13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S1470-2045(20)30450-2","article-title":"A\u00a0multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.esmoop.2024.102388_bib16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.annonc.2023.05.012","article-title":"Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer","volume":"34","author":"Villacampa","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamaoncol.2023.0181","article-title":"Assessment of the HER2DX assay in patients with ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab","volume":"9","author":"Waks","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2023.0187","article-title":"Assessment of a genomic assay in patients with ERBB2-positive breast cancer following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab","volume":"9","author":"Bueno-Mui\u00f1o","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104320","article-title":"HER2DX genomic test in HER2-positive\/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: a correlative analysis from the PerELISA trial","volume":"85","author":"Guarneri","year":"2022","journal-title":"eBioMedicine"},{"issue":"1 suppl 4","key":"10.1016\/j.esmoop.2024.102388_bib21","article-title":"Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials","volume":"8","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13073-015-0131-9","article-title":"The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine","volume":"7","author":"Saal","year":"2015","journal-title":"Genome Med"},{"key":"10.1016\/j.esmoop.2024.102388_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41523-022-00465-3","article-title":"RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer","volume":"8","author":"Staaf","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2024.102388_bib24","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012118","article-title":"The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome","volume":"12","author":"Brueffer","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.esmoop.2024.102388_bib25","doi-asserted-by":"crossref","first-page":"pkab028","DOI":"10.1093\/jncics\/pkab028","article-title":"Preexisting somatic mutations of estrogen receptor alpha (ESR1) in early-stage primary breast cancer","volume":"5","author":"Dahlgren","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.esmoop.2024.102388_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101237","article-title":"13P analytical validation of HER2DX test for early-hER2+ breast cancer","volume":"8","author":"Torres","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.102388_bib27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.esmoop.2024.102388_bib28","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.esmoop.2024.102388_bib29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejca.2022.07.029","article-title":"Breast cancer mortality of older patients with and without recurrence analysed by novel multi-state models","volume":"174","author":"de Boer","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.102388_bib30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0962280208092301","article-title":"Multi-state models for the analysis of time-to-event data","volume":"18","author":"Meira-Machado","year":"2009","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.esmoop.2024.102388_bib31","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib32","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.23.00790","article-title":"Nine-week versus one-year trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: 10-year update of the ShortHER phase III randomized trial","volume":"41","author":"Conte","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102388_bib33","series-title":"Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis","author":"Loibl","year":"2023"},{"key":"10.1016\/j.esmoop.2024.102388_bib34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jnci\/djac227","article-title":"HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1","volume":"115","author":"Bras\u00f3-Maristany","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292400156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292400156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:32:58Z","timestamp":1761856378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292400156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S205970292400156X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102388","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a\u00a0comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network\u2014Breast dataset (SCAN-B)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102388"}}